SCHEMBL23458554

SCHEMBL23458554

CC(C)(C)OC(=O)c1ccc2cc(O)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
CLK1 P49759 1/20 0.49
DYRK1A Q13627 1/20 0.49
DYRK1B Q9Y463 1/20 0.49
ESR1 P03372 1/20 0.44
F12 P00748 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8390404 0.91 GABRA1 (0.50) NPC1RAB9AGABRA1GABRG2GABRB3
SCHEMBL29912865 0.84 KDM4E (0.56) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL6370340 0.84 KDM4E (0.56) GABRA1GABRG2GABRB3GABRA3GABRA2
SCHEMBL1415273 0.84 CES2 (0.55) KMT2AMEN1NPC1RAB9AGABRA1
SCHEMBL25736545 0.83 GABRA1 (0.44) NPC1RAB9AGABRA1GABRG2GABRB3
SCHEMBL539749 0.83 CES2 (0.48) KMT2AMEN1NPC1RAB9AGABRA1
SCHEMBL3526930 0.81 PLAU (0.45) KMT2AMEN1RAB9AF12GABRA1
SCHEMBL38810 0.81 CA12 (0.59) KMT2AMEN1NPC1RAB9AESR1
SCHEMBL30371904 0.80 CA1 (0.64) KMT2AMEN1NPC1RAB9ACLK1
SCHEMBL363156 0.80 CA1 (0.64) KMT2AMEN1NPC1RAB9ACLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046947-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2023-02-16 US disclosed
US-20230046947-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2023-02-16 US disclosed
CN-115279416-A Reactive conjugates 德彪药业国际股份公司 2022-11-01 CN disclosed
EP-4069311-A1 REACTIVE CONJUGATES Debiopharm Research & Manufacturing SA (CH) 2022-10-12 EP disclosed
WO-2021110860-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2021-06-10 WO disclosed
WO-2021110860-A1 REACTIVE CONJUGATES DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) 2021-06-10 WO disclosed
CN-104768914-A Method for producing 6,6'-(ethylenedioxy)di-2-naphthoic acid diester TEIJIN LTD 2015-07-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046947-A1 REACTIVE CONJUGATES FCGR3B, FCGR1A, FCGR2A KMT2A 1155/4885MEN1 221/4885NPC1 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.